AstraZeneca Respiratory & Inflammation Research - asthma, rhinitis, COPD, rheumatoid arthritis

Respiratory & Inflammation (R&I)

We aim to build on our strong position in asthma treatment through the growth of key products, particularly Symbicort, new indications and market launches and the successful introduction of novel approaches to other areas of inflammatory disease such as severe chronic obstructive pulmonary disease (COPD) and Rheumatology.

Medical need

The WHO estimates that 100 million people worldwide suffer from asthma and more than twice that from COPD, which is currently the fifth leading cause of death in the world with further increases in the prevalence and mortality of the disease predicted for the coming decades.

Learn more about our Respiratory & Inflammation pipeline